641571-10-0

GPTKB entity

Statements (15)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkbp:canBe osteoarthritis
pain management
peripheral neuropathy
gptkbp:CASNumber gptkb:641571-10-0
gptkbp:clinicalTrialPhase Phase II
gptkbp:developedBy gptkb:Pfizer
gptkbp:drugClass FAAH inhibitor
gptkbp:hasMolecularFormula C23H20F3N3O2
https://www.w3.org/2000/01/rdf-schema#label 641571-10-0
gptkbp:IUPACName 4-[2-(3-cyanopyridin-2-yl)-1H-indol-5-yl]-N-(2,2,2-trifluoroethyl)piperazine-1-carboxamide
gptkbp:molecularWeight 427.42 g/mol
gptkbp:synonym gptkb:PF-04457845
gptkbp:bfsParent gptkb:Tasigna
gptkbp:bfsLayer 5